Table 2.
Glycaemic control of pregnancy trial participants based on available HbA1c data
| CGM | Control | p value | |
|---|---|---|---|
| Baseline | 6·83% (0·67) | 6·95% (0·66) | ·· |
| 24 weeks' gestation | 6·23% (0·53) | 6·40% (0·68) | ·· |
| Change from baseline to 24 weeks | −0·67 (0·58) | −0·52 (0·55) | 0·0374 |
| 34 weeks' gestation | 6·35% (0·57) | 6·53% (0·70) | ·· |
| Change from baseline to 34 weeks | −0·54 (0·62) | −0·35 (0·65) | 0·0372 |
| Achieved HbA1c≤6·5% (48 mmol/mol) at 34 weeks | 63/95 (66%) | 48/92 (52%) | 0·0601 |
Data are mean percentage (SD). Assessed in 99 participants in the CGM group and 96 participants in the control group at baseline, and in 95 participants in the CGM group and 92 participants in the control group at baseline and 34 weeks' gestation. Percentage point changes are either cross-sectional on participants with data for baseline, week 24, and week 34 values, or summaries of change on participants with data at the relevant timepoints. p values are from linear regression (HbA1c) or logistic regression (HbA1c<6·5%) on available data, controlling for baseline HbA1c and method of insulin delivery. CGM=continuous glucose monitoring. HbA1c=glycated haemoglobin.